Benefit assessment at Winicker Norimed
Our highly-qualified staff with years of industry experience are the key to your success
The benefit assessment of new medicinal products within the context of the AMNOG, the German Pharmaceuticals Market Reorganisation Act, has far-reaching economic consequences for the respective company. This is why we provide our clients consulting based on the latest science and data, not only in terms of medical and scientific issues, but in particular on how to demonstrate a medicinal product’s benefit after authorization in compliance with applicable legal requirements.
Our highly-qualified employees, most of whom have years of experience in the pharmaceutical industry, will be happy to advise you on the complex topics and various issues that arise over the lifecycle of a medicinal product – a major success factor for marketing your product.
Our range of services
in benefit assessment
- Strategic consulting for market access regarding benefit assessment procedures
- Consulting in the context of advisory boards
- Preparation of and assistance for consultations of the GBA (German Federal Joint Committee)
- Preparation of benefit assessment dossiers in accordance with §35a SGB V (volume V of the Social Insurance Code) or the GBA code of conduct, respectively – single modules or complete dossiers
- Consulting during the development process to establish an evidence base
- Methodological advice
- Conduct of systematic reviews, meta-analyses, indirect comparisons
- Study concepts to demonstrate the benefit, additional benefit and cost advantage
Winicker Norimed GmbH
Deutschherrnstraße 15-19, 90429 Nuremberg
Phone: +49 (0) 911 / 9 26 80 – 0
Fax: +49 (0) 911 / 9 26 80 – 8839
E-Mail: wn@winicker-norimed.com